CAJ | 학술논문

尽管对卵巢癌患者成功地施行了细胞减灭术及联合化疗，复发仍是一个难以克服的问题。因此探索新的治疗策略已成当务之急。生物靶向治疗曾被探索作为克服化疗对抗的手段，其中研究最多的可算是贝伐单抗。在Ⅱ、Ⅲ期临床试验中显示贝伐单抗是较有希望的生物靶向治疗药物。深入了解卵巢癌的基因调控信号通路，使更多的生物靶向治疗药物进入临床试验，将为卵巢癌治疗开辟新的天地。
진관대란소암환자성공지시행료세포감멸술급연합화료，복발잉시일개난이극복적문제。인차탐색신적치료책략이성당무지급。생물파향치료증피탐색작위극복화료대항적수단，기중연구최다적가산시패벌단항。재Ⅱ、Ⅲ기림상시험중현시패벌단항시교유희망적생물파향치료약물。심입료해란소암적기인조공신호통로，사경다적생물파향치료약물진입림상시험，장위란소암치료개벽신적천지。
Despite multimodel chemotherapy after successful surgical cytoreduction for ovarian cancer,disease recurrence continues to be problematic. Therefore, exploring new treatment strategy has already become urgent matter of the moment. Biological targeted therapies have been studied to overcome chemotherapy resistance. The most promising one at this time is bevacizumab. Results from phase Ⅱ and phase Ⅲ trials were excited. Deeper understanding of biologic pathway in ovarian cancer, and more biologic targets undergoing clinical trial will develop a new world for the treatment of ovarian cancer.